<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05617729</url>
  </required_header>
  <id_info>
    <org_study_id>Povinez001</org_study_id>
    <nct_id>NCT05617729</nct_id>
  </id_info>
  <brief_title>A Clinical Simulation Study of a Test Material on the Anterior Nares</brief_title>
  <official_title>A Clinical Simulation Study of a Test Material on the Anterior Nares</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center for Innovation and Research Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Center for Innovation and Research Organization</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is simulate the clinical use of a test material within a 24h&#xD;
      window. Efficacy will be simulated as the capacity of the material to reduce or clear the&#xD;
      anterior nares bacterial population from opportunistic pathogens (e.g. Staphylococcus Aureus,&#xD;
      Escherichia Coli, etc).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 7, 2022</start_date>
  <completion_date type="Actual">March 31, 2022</completion_date>
  <primary_completion_date type="Actual">March 18, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Colony Forming Units</measure>
    <time_frame>up to 24 hours following application</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Colonization, Asymptomatic</condition>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>this treatment consists of sterile saline that is applied to the nares using a swab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Povidone-iodine based gel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>this treatment consists of a Povidone-Iodine based gel that is applied to the nares using a swab</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline applied via swab</intervention_name>
    <description>sterile saline applied via swab</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Povidone-iodine based gel</intervention_name>
    <description>gel applied via swab</description>
    <arm_group_label>Povidone-iodine based gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is male or female between 18 to 55 years of age;&#xD;
&#xD;
          2. Subject has normal nasal passage;&#xD;
&#xD;
          3. Subject has not history of chronic nasal passage disease (chronic rhinitis, chronic&#xD;
             sinusitis).&#xD;
&#xD;
          4. Subject is willing to have materials applied and follow the protocol;&#xD;
&#xD;
          5. Subject agrees to avoid exposure of the test sites to any chemical product and to&#xD;
             refrain from touching the area of application.&#xD;
&#xD;
          6. Subject agrees to refrain from getting the application site wet and scrubbing or&#xD;
             washing the test area with soap or applying powders, lotions or personal care products&#xD;
             to the area during the course of the study;&#xD;
&#xD;
          7. Subject agrees not to introduce any new cosmetic or toiletry products during the&#xD;
             study;&#xD;
&#xD;
          8. Subject is dependable and able to follow directions as outlined in the protocol and&#xD;
             anticipates being available for all study visits;&#xD;
&#xD;
          9. Subject is willing to participate in all study evaluations;&#xD;
&#xD;
         10. Subject is in generally good health;&#xD;
&#xD;
         11. Subject understands and is willing to sign an Informed Consent Form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Female subject is pregnant, nursing, planning a pregnancy, or not using adequate birth&#xD;
             control;&#xD;
&#xD;
          2. Subject has a chronic nasal disease (e.g sinusitis, rhinitis);&#xD;
&#xD;
          3. Subject has a bleeding disorder, immunologically compromised, recent&#xD;
             illness/vaccination or currently febrile;&#xD;
&#xD;
          4. Subject reports a history of allergies to antiseptics;&#xD;
&#xD;
          5. Subject is currently taking certain medications which, in the opinion of the Principal&#xD;
             Investigator, may interfere with the study;&#xD;
&#xD;
          6. Subject has known allergies to skin treatment products or cosmetics, toiletries,&#xD;
             and/or topical drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Center for Innovation and Research Organization</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 8, 2022</study_first_submitted>
  <study_first_submitted_qc>November 8, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2022</study_first_posted>
  <last_update_submitted>November 8, 2022</last_update_submitted>
  <last_update_submitted_qc>November 8, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asymptomatic Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Povidone-Iodine</mesh_term>
    <mesh_term>Povidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

